Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 08, 2026 | May 12, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director | May 25, 2018 | May 29, 2018 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,851 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 1,438 · Balance 3,851 F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
Merck & Co., Inc.
Report date May 25, 2018 · Filed May 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 31,809.8934 |
Reported balance
After 2018-05-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-25 · Grant · Acquired 3,130.8174 · Balance 31,809.8934 F1: 1-for-1 F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3: Holdings include shares acquired in dividend reinvestment transactions. |
| Common StockSEC Table I · non-derivative | Direct | 3,352 |
Reported balance
Holding disclosure · report date 2018-05-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,352 |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3: Holdings include shares acquired in dividend reinvestment transactions.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 775 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 775 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 12, 2026 20:22 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,438 | $177.62 | $255,417.56 |
DisclosureSEC source: 0001100682-26-000068 · form4.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,851 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001423419-26-000001 · edgardoc.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001423419-26-000001 · edgardoc.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,076 | $134.98 Strike: $134.98 | $280,218.48 |
DisclosureSEC source: 0001127602-25-015491 · form4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,076 Underlying: Common Stock · 2,076 shares Expires 2035-05-21 F2 · shares: The stock options become exercisable upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 946 | $134.98 | $127,691.08 |
DisclosureSEC source: 0001127602-25-015491 · form4.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,413 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000011 · edgardoc.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000011 · edgardoc.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,311 | $228.41 Strike: $228.41 | $299,445.51 |
DisclosureSEC source: 0001127602-24-015529 · form4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,311 Underlying: Common Stock · 1,311 shares Expires 2034-05-13 F2 · shares: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 559 | $228.41 | $127,681.19 |
DisclosureSEC source: 0001127602-24-015529 · form4.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,467 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001883850-24-000001 · edgardoc.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 1,607 shares Expires 2034-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000001 · edgardoc.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2023 Filed May 17, 2023 19:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,669 | $192.36 Strike: $192.36 | $321,048.84 |
DisclosureSEC source: 0001127602-23-015868 · form4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,669 shares Expires 2033-05-15 F2 · shares: The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 19:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 664 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015868 · form4.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 908 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 02:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 592 | $218.40 Strike: $218.40 | $129,292.80 |
DisclosureSEC source: 0001127602-23-000743 · form4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592 Underlying: Common Stock · 592 shares Expires 2033-01-03 F2 · shares: The Stock Options become exercisable 1/03/2024. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 02:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 244 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-000743 · form4.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244 F1 · shares: Consists of 244 unvested restricted stock units that vest on 1/03/2024. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 477 | $0.00 Strike: $725.89 | $0.00 |
DisclosureSEC source: 0001883850-23-000011 · edgardoc.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477 Underlying: Common Stock · 477 shares Expires 2033-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 40 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000011 · edgardoc.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,216 | $0.00 Strike: $715.56 | $0.00 |
DisclosureSEC source: 0001104659-22-106311 · tm2226377-2_4seq1.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,216 Underlying: Common Stock · 3,216 shares Expires 2032-10-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 279 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-106311 · tm2226377-2_4seq1.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009927 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,809.8934 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 653 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017564 · form4.xml · nonDerivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,586 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 8, 2018. The restricted stock units vest upon the earlier of 5/14/2019 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017564 · form4.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,933 F1 · kind: Consists of 2,004 unvested restricted stock units that vest upon the earlier of 5/14/2019, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 26, 2017 Filed May 30, 2017 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,618.6075 | $64.92 | $170,000.00 |
DisclosureSEC source: 0001225208-17-010559 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,773.1335 Underlying: Common Stock · 2,618.6075 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 12, 2017 Filed May 16, 2017 15:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-018192 · form4.xml · nonDerivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,929 F2 · kind: This grant was made in lieu of director services fees for the term commencing May 9, 2017. The restricted stock units vest upon the earlier of 5/12/2018, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 12, 2017 Filed May 16, 2017 15:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-018192 · form4.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,136 F1 · kind: Consists of 2,436 unvested restricted stock units that vest upon the earlier of 5/12/2018, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 27, 2016 Filed May 31, 2016 19:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,009.915 | $56.48 | $170,000.00 |
DisclosureSEC source: 0001225208-16-034173 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,408.591 Underlying: Common Stock · 3,009.915 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2015 Filed Jun 1, 2015 18:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,463.4587 | $60.89 | $150,000.00 |
DisclosureSEC source: 0001225208-15-013057 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,686.6487 Underlying: Common Stock · 2,463.4587 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 30, 2014 Filed Jun 3, 2014 17:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,592.4646 | $57.86 | $150,000.00 |
DisclosureSEC source: 0001225208-14-014286 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,684.4086 Underlying: Common Stock · 2,592.4646 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 31, 2013 Filed Jun 3, 2013 19:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,211.9914 | $46.70 | $150,000.00 |
DisclosureSEC source: 0001225208-13-013655 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,577.1354 Underlying: Common Stock · 3,211.9914 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2012 Filed May 29, 2012 19:22 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,994.6738 | $37.55 | $150,000.00 |
DisclosureSEC source: 0001225208-12-013304 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,935.0298 Underlying: Common Stock · 3,994.6738 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 27, 2011 Filed May 31, 2011 14:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 4,142.5021 | $36.21 | $150,000.00 |
DisclosureSEC source: 0001225208-11-015344 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,641.0541 Underlying: Common Stock · 4,142.5021 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 04, 2010 Filed Aug 6, 2010 15:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-10-018709 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning August 4, 2011. Read SEC document |
| May 28, 2010 Filed Jun 1, 2010 20:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,632.5319 | $33.69 | $55,000.00 |
DisclosureSEC source: 0001225208-10-014305 · doc4.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,395.0709 Underlying: Common Stock · 1,632.5319 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerCommon Stock | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021812 · doc4.xml · nonDerivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,352 F1 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021812 · doc4.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 F1 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement. Read SEC document |
| November 03, 2009 Filed Dec 10, 2009 20:14 UTC Amendment | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 747.2123 | $30.67 Strike: $0.00 | $22,917.00 |
DisclosureSEC source: 0001225208-09-024286 · doc4a.xml · derivative · entry 2 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747.2123 Underlying: Common Stock · 747.2123 shares Expires not disclosed F3 · derivative.exercise_price: 1-for-1 F4 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F4 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
| November 03, 2009 Filed Dec 10, 2009 20:14 UTC Amendment | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-024286 · doc4a.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 F1 · shares: The line item is not new or revised, but was reported in error, and the purpose of this amendment is to delete the specified item. F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement. F1 · balance_after: The line item is not new or revised, but was reported in error, and the purpose of this amendment is to delete the specified item. Read SEC document |
| June 01, 2009 Filed Jun 2, 2009 16:54 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 1,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000310158-09-000079 · tho742.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 F1 · security: Shares acquired pursuant to the Directors Compensation Plan. F2 · price: Not Applicable. Read SEC document |
| December 01, 2008 Filed Dec 1, 2008 22:57 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 2,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000310158-08-000103 · tho693.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,247 F1 · security: Shares acquired pursuant to the Directors Compensation Plan. F2 · price: Not Applicable. Read SEC document |
| May 30, 2008 Filed May 30, 2008 21:50 UTC | Merck & Co., Inc. SGP · Entity 2807 | GrantCommon Shares | 1,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000310158-08-000072 · tho679.xml · nonDerivative · entry 1 Thompson Craig B. · CIK 0001423419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680 F1 · security: Shares acquired pursuant to the Directors Compensation Plan. F2 · price: Not Applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.